The president of the community of madrid, isabel díaz ayuso, visits the facilities of the pharmaceutical company normon in tres cantos

The President of the Community of Madrid, Isabel Díaz Ayuso, made an official visit today to Normon’s facilities in Tres Cantos, accompanied by the Regional Minister of Health, Fátima Matute Teresa, and the Mayor of Tres Cantos, Jesús Moreno García.

Together with Jesús Govantes Esteso, President of Normon; Jesús Govantes García, CEO of the company; and Gonzalo Fernández Govantes, Deputy General Manager of the company, they visited the manufacturing plant to learn about Normon’s key role in the industrial and healthcare development of the community.

During the visit led by Alicia Govantes Esteso, Technical Director of Normon, the institutional representatives learned first-hand about the drug manufacturing processes and the technological innovations that Normon is implementing to improve the efficiency and sustainability of its manufacturing operations, recognized as one of the most advanced in Europe. With a strong commitment to the future, the pharmaceutical company plans to invest nearly 300 million euros over the next five years, with the aim of continuing to grow, generating high-quality employment, and contributing to a more sustainable, accessible, and robust healthcare system.

During this visit, important topics were discussed, such as the current proposed Medicines Act and how it may impact the industrial sustainability of the pharmaceutical sector in Spain. Facilitating the entry of drugs manufactured outside Europe could significantly worsen drug shortages in Spain, jeopardize the production system within the pharmaceutical industry, and threaten job creation in our country.

The importance of energy availability was also addressed, in order to ensure a sufficient electricity infrastructure to support the industrial growth of our region and avoid the risk of compromising investments and production capacity.

In the words of Jesús Govantes Esteso: “Thank you for joining us today on this very meaningful and important visit for all of us at Normon. We need the support of public administrations, not only in economic terms, but also in recognizing the value we bring as an industry to the country. We would like to reiterate our willingness to collaborate, engage in dialogue, and contribute whenever we are needed”.

Normon, a 100% Spanish family-owned laboratory, is a benchmark in the pharmaceutical sector in our country, with a clear purpose: facilitating access to high-quality treatments to care for people’s health. Every day, more than 3,200 professionals work with that purpose in mind.

As pioneers in launching the first generic drugs in Spain, Normon now offers the most comprehensive vade mecum on the market, with more than 340 active substances. Every second, four Normon treatments are dispensed in pharmacies across Spain. In 2024, the company manufactured more than 345 million units and nearly 5 billion doses.

In the hospital sector, Normon is also present in nearly all clinics and hospitals across the country, holding a 19.1% share of units in the hospital market.

In addition, Normon has been supporting dentists for more than 30 years; one out of every two patients is treated with its dental anesthesia, making it a benchmark in this sector.

The Normon OTC line continues to grow, with solutions designed for well-being and self-care, a key commitment for the company’s future.

Press contact: comunicacion@normon.com